Who are Vasopressin, Arginine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): low-dose epinephrine and tranexamic acid, vasopressin - early initiation, Vasopressin intravenous infusion, Angiotensin II Infusion, Intracervical injection of Vasopressin, Early Vasopressin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vasopressin-arginine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Vasopressin, Arginine — Competitive Intelligence Brief

Vasopressin, Arginine (Vasopressin, Arginine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vasopressor agent; antidiuretic hormone. Area: Cardiovascular; Endocrinology; Hemostasis.

marketed Vasopressor agent; antidiuretic hormone Vasopressin receptors (V1a, V1b, V2) Cardiovascular; Endocrinology; Hemostasis Small molecule Live · refreshed every 30 min

Target snapshot

Vasopressin, Arginine (Vasopressin, Arginine) — Lars Wiuff Andersen. Arginine vasopressin is a peptide hormone that binds to vasopressin receptors to increase blood pressure, promote water reabsorption in the kidneys, and enhance blood clotting.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Vasopressin, Arginine TARGET	Vasopressin, Arginine	Lars Wiuff Andersen	marketed	Vasopressor agent; antidiuretic hormone	Vasopressin receptors (V1a, V1b, V2)
low-dose epinephrine and tranexamic acid	low-dose epinephrine and tranexamic acid	King Abdullah International Medical Research Center	marketed	Combination hemostatic and vasopressor agent	Alpha-1 and beta-1 adrenergic receptors (epinephrine); plasminogen and plasmin (tranexamic acid)
vasopressin - early initiation	vasopressin - early initiation	The Cleveland Clinic	marketed	Vasopressor agent	Vasopressin receptor (V1 and V2)
Vasopressin intravenous infusion	Vasopressin intravenous infusion	University of Sao Paulo	marketed	Vasopressor agent; antidiuretic hormone	Vasopressin receptor V1a, V1b, and V2
Angiotensin II Infusion	Angiotensin II Infusion	Massachusetts General Hospital	marketed	Vasopressor agent	Angiotensin II receptor (AT1 and AT2)
Intracervical injection of Vasopressin	Intracervical injection of Vasopressin	Prisma Health-Upstate	marketed	Vasopressor agent	V1 vasopressin receptor
Early Vasopressin	Early Vasopressin	Hospital do Coracao	phase 3	Vasopressor agent	V1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vasopressor agent; antidiuretic hormone class)

Lars Wiuff Andersen · 1 drug in this class
University of Sao Paulo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vasopressin, Arginine — Competitive Intelligence Brief. https://druglandscape.com/ci/vasopressin-arginine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab